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Objectives: Cigarette smoking is the most important risk factor for urinary bladder cancer. The prognostic effect of cigarette smoking on
disease recurrence and progression in patients with non–muscle-invasive bladder cancer (NMIBC), however, is still unclear. We evaluated
the effect of smoking status and intensity, and timing of smoking cessation, on NMIBC prognosis.
Methods and materials: A population-based series of patients diagnosed with NMIBC from 1995 until 2010 was identiﬁed through the
Netherlands Cancer Registry. Self-reported smoking history was obtained by a postal lifestyle questionnaire at study inclusion. Detailed
clinical data concerning diagnosis, treatment, and disease course were collected retrospectively through a medical ﬁle survey. The
association of smoking variables with recurrence- and progression-free survival of 963 patients with primary NMIBC was studied using
cumulative incidence curves and competing risk regression analyses.
Results: The study population comprised 181 never smokers (18.8%), 490 former smokers (50.9%), and 292 current smokers (30.3%) at
the time of diagnosis. No statistically signiﬁcant difference or trend in risk of recurrence (Ptrend ¼ 0.47) or progression (Ptrend ¼ 0.23)
across the 3 smoking status categories was found. Moreover, no dose-response association was observed across categories of smoking
quantity, duration, or cumulative exposure in relation to NMIBC prognosis. The timing of smoking cessation (i.e., ceased smokingZ10 y
before diagnosis,o10 y before diagnosis, vs. current smoker at diagnosis) did not signiﬁcantly affect the risk of recurrence (Ptrend ¼ 0.31)
and progression (Ptrend ¼ 0.19).
Conclusions: Based on our study, smoking status, smoking intensity, or cessation at any time before diagnosis does not seem to alter the
risks of recurrence and progression among patients with NMIBC. Patients’ smoking history is not useful for the guidance of clinical
management decisions. Patients should nevertheless be advised to quit considering the known beneﬁcial effects on other non-NMIBC–
related end points such as cardiovascular disease and second primary cancers. r 2014 Elsevier Inc. All rights reserved.
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The relapsing nature of non–muscle-invasive bladder
cancer (NMIBC) requires frequent follow-up visits and
repeated treatment [1,2]. Therewith, NMIBC poses an
enormous burden on patients and health care systems..urolonc.2014.06.002
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iemeney@radboudumc.nl (L.A. Kiemeney).Smoking is the most important risk factor for urinary
bladder cancer (UBC), with 50% of all UBC attributable
to it [3]. Smoking cessation results in a decrease in the risk
of primary UBC of 30% after 1 to 4 years and 60% to 70%
after 25 or more years [4,5].
Although not extensively investigated, lifestyle may also
affect disease prognosis, and it could therefore represent
exposures to be avoided or stimulated after the diagnosis is
made. Many substances in cigarette smoke are associated
A.J. Grotenhuis et al. / Urologic Oncology: Seminars and Original Investigations 33 (2015) 65.e9–65.e1765.e10with carcinogenesis of the bladder wall [6]. In addition to a
role as initiators of urothelial carcinogenesis, tobacco
constituents could exert (direct) tumor-promoting effects
through mechanisms such as immunomodulation [7,8].
Through this, past smoking exposure could affect the
clinical features and consequently the malignant potential
of bladder tumors at the ﬁrst clinical presentation [9].
Termination of tobacco exposure might favorably alter the
disease course of patients.
Despite the increasing number of studies investigating the
prognostic effect of tobacco smoking among patients with
UBC, no ﬁrm conclusions can be drawn yet [10]. Evidence for
prognostic implications of (past or continued) cigarette smok-
ing exposure would emphasize the importance of urologists in
stimulating patient awareness and smoking cessation. Besides,
it could highlight the relevance of ascertainment of patients’
smoking history for clinical management decisions. We
investigated the prognostic effect of smoking status, smoking
intensity, and timing of cessation on the risk of recurrence and
progression among a large Dutch population-based series of
patients with NMIBC.2. Materials and methods
2.1. Patient population
This study used data of the Nijmegen Bladder Cancer
Study (NBCS) [11]. Patients with UBC diagnosed in 1 of
7 hospitals in the mideastern part of the country were
identiﬁed through the population-based Netherlands Cancer
Registry (NCR) held by the Comprehensive Cancer Center
the Netherlands. Patients younger than 75 years at the time
of diagnosis were invited to the NBCS by Comprehensive
Cancer Center the Netherlands on behalf of the patients’
treating physicians. The NBCS started in May 2007 with
invitation of patients diagnosed with UBC from 1995 to
2006 who were still alive. Later, the NBCS was expanded
with 3 more recently diagnosed patient cohorts (2006–2008,
2008–2009, and 2009–2010) in 3 phases (January 2009,
November 2010, and February 2012, respectively). Of all
the invitees, 66% agreed to participate. All participants gave
written informed consent, and the study was approved by
the institutional review board of the Radboud university
medical center (Nijmegen, the Netherlands).
For the current analysis, we included patients with NMIBC
(stages Ta, T1, and carcinoma in situ [CIS]) at the ﬁrst
diagnosis, with a maximum time from diagnosis until recruit-
ment of 5 years. Reason for using this time window was to
minimize chance of bias owing to prevalent sampling or
problems with recall of smoking history. We excluded patients
with a previous or synchronous (i.e., within 3 mo) diagnosis of
upper urinary tract cancer based on NCR information. Vital
status of patients at December 31, 2012 was obtained through
record linkage of NCR data with the Dutch Municipal
Personal Records Database. Detailed clinical data concerningdiagnosis, treatment, and disease course were collected retro-
spectively through a medical ﬁle survey.
2.2. Smoking assessment
At study inclusion, self-reported smoking history of
participants was determined by a postal lifestyle question-
naire. Data were collected concerning smoking status
(never, former, and current) at recruitment; age at smoking
initiation and cessation; the (average) number of cigarettes,
cigars, and pipe smoked per day; and number of years of
smoking cigarettes, cigars, and pipe. In case of intermittent
periods of smoking cessation, patients were asked to sum
the years of the periods they smoked.
In this study, “never smokers” (NS) were deﬁned as
patients who reported to have never smoked cigarettes.
Among ever cigarette smokers, smoking status at diagnosis
was determined. For this, timing of smoking cessation was
calculated as the difference between the age at diagnosis (i.e.,
age at the initial transurethral resection of the tumor [TURT])
and reported age at cessation. The category of “current
smokers (CS)” comprised individuals who still smoked in
the year of their diagnosis. This group was further stratiﬁed in
2 groups: those who quitted smoking within 1 year after their
diagnosis (“quitters”) and those who did not (“continuing
smokers”). Among patients who quitted smoking before
diagnosis (i.e., “former smokers (FS)”), 2 strata were deﬁned
based on the time elapsed since smoking cessation (o10
orZ10 y). All analyses were repeated after excluding 61 and
146 cigar and pipe smokers from the never and ever cigarette
smokers category, respectively.
In continuing smokers, only the smoking years before
diagnosis were considered. Cumulative smoking exposure
was expressed in pack-years, calculated by multiplying
cigarette smoking duration in years and number of ciga-
rettes per day divided by 20.
2.3. Veriﬁcation of smoking status categorization
A telephone survey was performed to verify timing of
smoking cessation with respect to diagnosis. For this
survey, we selected a subset of patients who reported an
age at cessation within 2 years before or after their age at
diagnosis. In total, 46 of the 96 patients matching these
criteria and still alive were contacted. Results of this survey
are summarized in Table S1. In general, our smoking status
categorization was judged to be valid based on this survey.
However, the survey highlighted the difﬁculty in accurately
distinguishing patients who quitted shortly before or after
diagnosis, and quitters from continuing smokers.
2.4. Outcome deﬁnition and statistical analyses
Patient and tumor characteristics were compared among
the 3 smoking categories using chi-square, Fisher exact, and
one-way analysis of variance tests where appropriate.
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progression-free survival (RFS and PFS). Recurrence was
deﬁned as a new, histologically conﬁrmed bladder or
prostatic urethra tumor following at least 1 tumor-negative
follow-up cystoscopy result or 2 surgical resection sessions
for the primary tumor. Progression was deﬁned as the ﬁrst
occurrence of grade progression, stage progression, local or
distant metastasis, and cystectomy for therapy-resistant
(“uncontrollable”) disease. In addition, we used a stricter
progression deﬁnition, i.e., transition to muscle-invasive
bladder cancer (MIBC; ZT2). Patients with NMIBC who
had an immediate radical cystectomy after primary diag-
nosis (n ¼ 21) were considered not at risk of (intravesical)
disease recurrence and progression to MIBC and were
therefore excluded.
To evaluate the association between smoking and
NMIBC recurrence and progression, competing risk analy-
ses were conducted, as smoking is associated with several
health problems that increase mortality. RFS and PFS were
deﬁned as the time period between date of the initial TURT
and date of the ﬁrst event (recurrence or progression,
respectively), date of the last urological checkup, date of
death (during urological follow-up), or date of 5-year
follow-up, whichever came ﬁrst. Death was treated as a
competing event. For progression to MIBC, radical cystec-
tomy (without a prior or simultaneous event) was also
treated as competing event.
Cumulative incidence curves were constructed and
compared among the 3 smoking strata using Gray’s test [12].
Univariable and multivariable competing risk regression
analyses were used to calculate subdistribution hazard
ratios and 95% CIs for smoking variables in relation to
prognosis [13]. In a ﬁrst multivariable model, smoking
status (never/ever and never/former/current) was included in
conjunction with the prognostic factors tumor stage, grade,
and focality; concomitant CIS; and initial treatment. A
second multivariable analysis was performed to simultane-
ously evaluate the prognostic relevance of (cigarette) smoking
intensity and timing of smoking cessation among the subset
of ever smokers, again in conjunction with aforementioned
prognostic factors. Smoking intensity was entered once as the
combination of cigarette smoking quantity and duration, and
alternatively as the combined cumulative exposure measure.
All univariable and multivariable models were ﬁtted by
entering smoking variables as categorical variables. A possi-
ble dose-response relationship was evaluated by entering
smoking variables as ordinal variables, and statistical signiﬁ-
cance was tested using the Wald test. A two-sided Po 0.05
was considered statistically signiﬁcant.
Missing treatment values were imputed with the most
frequent treatment category in the data set for each corre-
sponding combination of tumor stage, grade, and concomitant
CIS. Multiple imputation of missing values for tumor focality
was conducted using SPSS v20.0 (IBM Corp., Armonk, NY)
based on the joint distribution of tumor stage, grade,
concomitant CIS, treatment, recurrence status, and tumorfocality. For each missing value, 5 imputations were gen-
erated. Model estimates of multivariable regression analyses
were pooled across the 5 resulting data sets.
Statistical analyses were performed using R v3.0.1 with
packages cmprsk and mitools.3. Results
3.1. Patient characteristics
The study population consisted of 963 patients with
newly diagnosed NMIBC. Median time from the initial
TURT until date of the last urological checkup was 3.7
years (interquartile range: 2.7–4.7). Distribution of the
timing of smoking assessment with respect to NMIBC
diagnosis was as follows: 76 (7.9%) within 1 year, 379
(39.4%) between 1 and 2 years, 299 (31.0%) between 2 and
3 years, 115 (11.9%) between 3 and 4 years, and 94 (9.8%)
between 4 and 5 years. The numbers in the 3 smoking status
strata were as follows: NS: 181 (18.8%), FS: 490 (50.9%),
and CS: 292 (30.3%). Among CS, 75 patients were quitters
and 217 were continuing smokers.
Descriptive characteristics by smoking status are shown
in Table 1. Notable differences between the strata are the
lower mean age in CS and the difference in the distribution
of sex. As expected, smoking duration and cumulative
exposure were higher among CS than FS. FS had a
signiﬁcantly higher and CS a lower proportion of high-
grade tumors compared with NS. The proportion of patients
who received adjuvant intravesical treatment was lower
among CS compared with NS and FS. All other variables
were comparable among the 3 strata.
3.2. Association of smoking status with NMIBC prognosis
During the ﬁrst 5 years after diagnosis, 368 patients with
NMIBC (cumulative incidence: 45.1%) had Z1 recurrence.
The 5-year cumulative incidence of NMIBC progression
was 17.2% (n ¼ 129 events). In 41 patients, this concerned
progression to MIBC, which corresponds to a 5-year
cumulative risk of 5.5%. Based on univariable analysis,
an increased risk of all 3 prognostic end points was
observed among ever smokers compared with NS, though
nonsigniﬁcant (P ¼ 0.53 for recurrence, and P ¼ 0.55 and
0.30 for broad and stricter deﬁnition of progression,
respectively) (Table 2). Categorization of the smokers group
revealed a tendency toward lower RFS and (in particular)
PFS among FS compared with NS/CS (Gray’s P ¼ 0.18
for recurrence, and P ¼ 0.03 for both progression types;
Fig.). There was no signiﬁcant trend in RFS and PFS across
the 3 smoking status categories (Table 2).
Also after adjustment for clinicopathological character-
istics and treatment, no signiﬁcant trend in clinical outcome
across the smoking categories was observed (Table 2).
Owing to the high number of missing values, we were
Table 1
Descriptive characteristics of 963 included patients with primary non–muscle-invasive bladder cancer (NMIBC) according to smoking status at diagnosis
n (%) Smoking status at diagnosis P valuea
Never (n ¼ 181) Former (n ¼ 490) Current (n ¼ 292)
Sex
Male 125 (69.1) 433 (88.4) 233 (79.8) o1  106
Female 56 (30.9) 57 (11.6) 59 (20.2)
Age at diagnosis, y
Mean  SD (range) 63  11 (29–92) 66  7.8 (32–91) 61  9.1 (25–81) o1  106
Smoking quantity (no. of cig./d)
Mean  SD (range) N/A 15.6  9.5 (1–70) 15.2  6.0 (1–40) 0.53
Unknown N/A 3 –
Smoking duration, yb
Mean  SD (range) N/A 26.9  12.9 (1–57) 39.0  12.8 (1–66) o1  106
Unknown N/A 27 18
Cum. smoking exposure (PYs)b
Mean  SD (range) N/A 22.4  17.9 (0.1–120) 30.2  15.5 (0.1–98) o1  106
Unknown N/A 30 18
Tumor stage
Ta 128 (72.3) 326 (67.4) 210 (73.2) 0.24
T1 41 (23.2) 142 (29.3) 65 (22.6)
CIS 8 (4.5) 16 (3.3) 12 (4.2)
Unknown 4 6 5
Concomitant CIS
No 165 (92.7) 448 (92.2) 267 (92.7) 0.96
Yes 13 (7.3) 38 (7.8) 21 (7.3)
Unknown 3 4 4
Tumor gradec
Low 116 (64.4) 278 (57.2) 194 (67.8) 0.01
High 64 (35.6) 208 (42.8) 92 (32.2)
Unknown 1 4 6
Tumor focalityd
Solitary 97 (57.7) 263 (55.8) 169 (59.9) 0.55
104 (57.5) 272 (55.5) 174 (59.6)
Multiple 71 (42.3) 208 (44.2) 113 (40.1)
77 (42.5) 218 (44.5) 118 (40.4)
Unknown 13 19 10
– – –
Tumor size
o3 cm 24 (55.8) 64 (59.3) 46 (65.7) 0.53
Z3 cm 19 (44.2) 44 (40.7) 24 (34.3)
Unknown 138 382 222
Initial treatmente
TURT only (1 p.o. i.v. CT instillation) 79 (43.9) 211 (43.5) 154 (52.7) 0.04
79 (43.6) 212 (43.3) 154 (52.7)
Adjuvant i.v. CT 62 (34.4) 162 (33.4) 78 (26.7)
63 (34.8) 164 (33.5) 78 (26.7)
Adjuvant i.v. IT 38 (21.1) 107 (22.1) 52 (17.8)
38 (21.0) 109 (22.2) 52 (17.8)
Both adjuvant i.v. CT and IT 1 (0.6) 4 (0.8) 8 (2.7)
1 (0.6) 4 (0.8) 8 (2.7)
Other – 1 (0.2) –
– 1 (0.2) –
Unknown 1 5 –
– – –
Note: Values in boldface type indicate signiﬁcance at P o 0.05.
cig. ¼ cigarettes; CT ¼ chemotherapy; Cum. ¼ cumulative; IT ¼ immunotherapy; i.v. ¼ intravesical; N/A ¼ not applicable; p.o. ¼ postoperative;
PYs ¼ pack-years; SD ¼ standard deviation.
aP value is based on chi-square, Fisher exact, or one-way ANOVA test, where appropriate. Missing data were not included in the calculation of P values.
bCorrected for smoking years after diagnosis in current smokers.
cLow grade: WHO 1973 differentiation grade 1 or 2, WHO/ISUP 2004 low grade, or Malmström (Modiﬁed Bergkvist) grade 1 or 2a; high grade: WHO
1973 differentiation grade 3, WHO/ISUP 2004 high grade, or Malmström (Modiﬁed Bergkvist) grade 2b or 3.
dThe ﬁrst line gives the numbers and percentages in the original data set. The second line gives the pooled numbers and percentages based on the 5 imputed
data sets (in each data set, 42 missing values for tumor focality are imputed).
eThe ﬁrst line gives the numbers and percentages in the original data set. The second line gives the numbers and percentages after single imputation of 6
missing values for treatment.
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Table 2
Univariable and multivariable analyses of smoking status in relation to risk of recurrence and progression among 963 patients with primary non–muscle-
invasive bladder cancer (NMIBC)
Prognostic end point Smoking status Univariable analysis Multivariable analysisa
n n Eventsb Crude sHR (95% CI) P valuec n n Eventsb Adj. sHR (95% CI) P valuec
Disease recurrence Never 181 63 1.00 (ref) 0.53 177 61 1.00 (ref) 0.68
Ever 782 305 1.09 (0.83–1.43) 765 298 1.06 (0.80–1.41)
Never 181 63 1.00 (ref) 0.52 177 61 1.00 (ref) 0.47
Former 490 202 1.18 (0.89–1.57) 482 199 1.14 (0.85–1.53)
Current 292 103 0.95 (0.70–1.31) 283 99 0.93 (0.67–1.29)
Disease progressiond Never 181 21 1.00 (ref) 0.55 177 20 1.00 (ref) 0.57
Ever 782 108 1.15 (0.72–1.83) 765 104 1.15 (0.72–1.84)
Never 181 21 1.00 (ref) 0.19 177 20 1.00 (ref) 0.23
Former 490 79 1.38 (0.85–2.22) 482 76 1.36 (0.84–2.21)
Current 292 29 0.80 (0.46–1.39) 283 28 0.80 (0.45–1.42)
Disease progressione Never 181 5 1.00 (ref) 0.30 177 4 1.00 (ref) 0.25
Ever 782 36 1.64 (0.64–4.18) 765 34 1.85 (0.65–5.28)
Never 181 5 1.00 (ref) 0.37 177 4 1.00 (ref) 0.54
Former 490 29 2.14 (0.83–5.51) 482 28 2.33 (0.82–6.65)
Current 292 7 0.84 (0.26–2.65) 283 6 0.92 (0.25–3.35)
Note: Owing to missing data for covariables, adjusted hazard ratios are based on a smaller number of patients.
Adj. ¼ adjusted; CI = conﬁdence interval; ref ¼ reference group; sHR ¼ subdistribution hazard ratio.
aEffect estimates are adjusted for the prognostic factors such as tumor stage (Ta/T1/CIS), tumor grade (high vs. low), concomitant CIS (yes vs. no), tumor
focality (multiple vs. solitary), and initial treatment (TURT only/adjuvant intravesical [i.v.] chemotherapy/adjuvant i.v. immunotherapy/both adjuvant i.v.
chemotherapy and immunotherapy). Effect estimates were pooled across the 5 data sets with imputations for missing values of tumor focality and treatment.
bNumber of events within 5 years after the ﬁrst non–muscle-invasive bladder cancer diagnosis.
cP value is based on Wald test derived from the univariable/multivariable model with smoking status included as ordinal variable.
dBroad progression deﬁnition (i.e., ﬁrst occurrence of grade progression, stage progression, occurrence of local metastasis or distant metastasis or both, and
cystectomy for therapy-resistant [“uncontrollable”] disease).
eStricter progression deﬁnition (i.e., transition from NMIBC [Ta, T1, CIS] to MIBC [ZT2]).
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cantly different after exclusion of cigar and pipe smokers
(data not shown).
3.3. Association of smoking intensity and timing of
cessation with NMIBC prognosis
We simultaneously evaluated the prognostic relevance of
smoking intensity and timing of cessation with adjustment
for tumor characteristics and treatment in the 782 ever
smokers (Table 3).
Based on the ﬁrst multivariable model (Model 1), no
dose-response association was observed across categories of
smoking quantity (Ptrend ¼ 0.62 and 0.95) or smoking
duration (Ptrend ¼ 0.61 and 0.15) in relation to recurrence
and progression, respectively. However, some indications
were found for a trend toward a lower risk of progression
with increasing smoking duration. In a second multivariable
model (Model 2), we included smoking intensity expressed
in pack-years. No signiﬁcant trend in RFS and PFS was
observed across the categories of cumulative exposure
(Ptrend ¼ 0.98 and 0.28, respectively). In both models, the
2 categories of FS were found to have (a nearly signiﬁcant)
higher risk of recurrence and progression than CS. Althoughthe increase in risk was less pronounced among patients who
quitted smokingZ10 years before diagnosis, longer time
since smoking cessation did not seem to beneﬁcially affect
disease prognosis (Table 3).
In a secondary analysis, we reran the multivariable
analyses with CS split into quitters and continuing smokers
(Table S2). This resulted in a negligible change in
point estimates and signiﬁcance level for the smoking
intensity measures. The increased risk of recurrence and
progression among both FS groups became more pro-
nounced compared with continuing smokers. Although
numbers were too small for a robust estimate, quitters were
found to have a nonsigniﬁcant increased risk of both end
points compared with continuing smokers in both models.
The small event number (n ¼ 36) among ever smokers
did not allow proper evaluation of these smoking variables
in relation to the stricter deﬁnition of progression (i.e., shift
to MIBC).4. Discussion
We did not ﬁnd evidence for an association of cigarette
smoking exposure with NMIBC prognosis. No consistent trend
Fig. Cumulative risk of disease recurrence and progression in patients with
non–muscle-invasive bladder cancer (NMIBC) by smoking status. Cumu-
lative incidence curves for (A) disease recurrence, (B) disease progression
according to broad deﬁnition, and (C) disease progression according to
stricter deﬁnition (i.e., progression to muscle-invasive disease) in non–
muscle-invasive bladder cancer (NMIBC) patients by smoking status. The
number of individuals at risk at speciﬁed time points in each of the
smoking groups is indicated below the plots. (Color version of ﬁgure is
available online.)
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observed across the 3 smoking status strata. Neither smoking
status at diagnosis nor smoking intensity was signiﬁcantly
associated with risk of recurrence or progression. The hypoth-
esis that (longer time since) smoking cessation improves
clinical outcome of patients with NMIBC was rejected.
A recent article by Crivelli et al. [10] describes the
current evidence base for prognostic relevance of smoking
in patients with urothelial carcinoma. Based on a literature
review, 14 studies (n ¼ 5,990) were identiﬁed that
evaluated the effect of smoking on clinical outcome among
patients with NMIBC. In half of these studies, this was not
the primary research aim. Most studies were of relatively
small sample size (n o 400), except for a study by
Sfakianos et al. [14] (n ¼ 623), one by Lammers et al.
[15] (n ¼ 718), and a multi-center study by Rink et al. [16]
(n ¼ 2,043). The review highlights extensive variation in
patient and tumor characteristics, treatment, follow-up
period, and exposure deﬁnition and assessment across
studies, which complicates comparison of results. Most
reviewed studies indicated that (increasing exposure to)
smoking is associated with worse RFS, though there is a
larger controversy on the effect on disease progression.
In 2014 edition of the European Association of Urology
guidelines, a recommendation was added that all smokers
with conﬁrmed NMIBC should be advised to stop smoking
because of the reported improvement in outcome following
smoking cessation [17]. However, the evidence supporting
this statement is rather limited, with conﬂicting results
across studies, as was also described in the review article
[10]. Most studies investigated the effect of smoking
cessation by comparing recurrence and progression risk
between CS and FS at diagnosis, and some did additionally
evaluate the effect of varying time elapsed since cessation
among FS. Serretta et al. [18] described increased risk of
recurrence in both FS and CS compared with NS (which
was more pronounced among FS). In a study by Lammers
et al. [15], no difference was found in recurrence risk
between patients who ceased smoking Z15 vs.o15 years
before diagnosis. By contrast, Rink et al. [16,19] concluded
thatZ10 years of cessation did abrogate the detrimental
effect of smoking on clinical outcome among both patients
with primary NMIBC and those with recurrent NMIBC.
Most studies used data concerning smoking status and
history that were assessed at diagnosis (sometimes collected
retrospectively from the medical charts), i.e., not collected
in a longitudinal fashion. Therefore, only few studies could
evaluate whether smoking cessation at diagnosis could
(still) beneﬁcially alter prognosis compared with continued
smoking after diagnosis. Fleshner et al. [20] found
increased risk of recurrence among continued smokers
compared with both quitters (i.e., quitted between 1 y
before and up to 3 mo after diagnosis) and ex-smokers
Table 3
Multivariable analysis of smoking intensity and timing of cessation in relation to risk of recurrence and progression among the subset of ever-smoking patients with primary non–muscle-invasive bladder cancer
(NMIBC)
n Disease recurrence Disease progressiona
n Eventsb Model 1c Model 2d n Eventsb Model 1c Model 2d
Adj. sHR (95% CI)e P valuef Adj. sHR (95% CI)e P valuef Adj. sHR (95% CI)e P valuef Adj. sHR (95% CI)e P valuef
Smoking quantity
(cig./d)
o10 113 37 1.00 (ref) 0.62 X X 16 1.00 (ref) 0.95 X X
10–20 504 207 1.24 (0.86–1.79) X 69 1.04 (0.58–1.87) X
420 100 41 1.22 (0.76–1.93) X 16 1.02 (0.48–2.18) X
Cigarette smoking
duration, yg
0.61o10 54 20 1.00 (ref) X X 8 1.00 (ref) 0.15 X X
10–19 110 49 1.05 (0.62–1.78) X 20 0.86 (0.37–1.98) X
20–29 151 53 0.83 (0.49–1.43) X 24 0.83 (0.37–1.87) X
30–39 161 61 0.88 (0.50–1.52) X 21 0.59 (0.25–1.40) X
Z40 241 102 1.02 (0.59–1.78) X 28 0.57 (0.25–1.33) X
Cumulative smoking
exposure (PYs)g
o20 297 108 X X 1.00 (ref) 0.98 43 X X 1.00 (ref) 0.28
20–39 286 131 X 1.29 (0.98–1.70) 46 X 1.08 (0.71–1.65)
40–59 115 42 X 1.01 (0.70–1.46) 10 X 0.67 (0.34–1.32)
Z60 19 4 X 0.56 (0.21–1.47) 2 X 0.55 (0.14–2.16)
Smoking status
(including timing
of cessation)h
Current 265 95 1.00 (ref) 0.31 1.00 (ref) 0.41 28 1.00 (ref) 0.19 1.00 (ref) 0.08
Formero10 y 106 52 1.38 (0.97–1.95) 1.36 (0.96–1.92) 19 1.68 (0.92–3.07) 1.62 (0.89–2.93)
FormerZ10 y 346 138 1.22 (0.88–1.68) 1.21 (0.91–1.60) 54 1.40 (0.85–2.30) 1.60 (0.98–2.60)
Note: Numbers do not add up to the total number of ever smokers (n ¼ 782) owing to missing data for 1 or more of the included covariables.
Adj. ¼ adjusted; CI = conﬁdence interval; cig. ¼ cigarettes; PYs ¼ pack-years; ref ¼ reference group; sHR ¼ subdistribution hazard ratio.
aBroad progression deﬁnition (i.e., ﬁrst occurrence of grade progression, stage progression, occurrence of local metastasis or distant metastasis or both, and cystectomy for therapy-resistant [“uncontrollable”]
disease)
bNumber of events within 5 years after the ﬁrst non–muscle-invasive bladder cancer diagnosis.
cIn Model 1, the following smoking variables are simultaneously included: smoking quantity, smoking duration, and smoking status.
dIn Model 2, the following smoking variables are simultaneously included: cumulative smoking exposure and smoking status.
eEffect estimates are adjusted for the prognostic factors such as tumor stage (Ta/T1/CIS), tumor grade (high vs. low), concomitant CIS (yes vs. no), tumor focality (multiple vs. solitary), and initial treatment
(TURT only/adjuvant intravesical [i.v.] chemotherapy/adjuvant i.v. immunotherapy/both adjuvant i.v. chemotherapy and immunotherapy). Effect estimates were pooled across the 5 data sets with imputations for
missing values of tumor focality and treatment.
fP value is based on Wald test derived from the multivariable model with all smoking variables included as ordinal variables.
gCorrected for smoking years after diagnosis.
hTime elapsed since smoking cessation was calculated as the difference between the age at diagnosis (i.e., age at the initial TURT) and reported age at cessation.
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et al. [21] also found worse RFS among continued smokers
compared with quitters, but ex- and nonsmokers did
experience (tendency toward) increased recurrence risk as
well. Sfakianos et al. did not detect a beneﬁcial effect of
smoking cessation at diagnosis on outcome among bacillus
Calmette-Guérin–treated patients with NMIBC [14].
Strengths of our study are the population-based nature
and relatively large sample size of well-phenotyped patients
with NMIBC with long follow-up. The fact that patients
with UBC were selected for study participation based on
their vital status may have led to selection of patients with a
relatively favorable prognosis. This could bias study results,
probably to a larger extent for progression than for
recurrence. Therefore, we restricted our analyses to a subset
of study participants who were recruited within 5 years after
diagnosis. In this sample, we expect selection is negligible
considering the high 5-year survival rates in patients with
NMIBC and that 78% of the sample was already enrolled
within 3 years of diagnosis.
In addition, restriction of the analyses to the patient sample
recruited within 5 years after diagnosis did decrease the chance
of bias related to patients’ ability to recall their smoking
history, especially for the period surrounding diagnosis.
In this study, patients were asked for their age at smoking
initiation and cessation, and smoking status and time elapsed
since cessation at diagnosis were derived from this. Therefore,
the precision of timing of cessation was not sufﬁcient to
(further) classify patients who ceased smoking shortly before
or after diagnosis, and to completely distinguish quitters from
continuing smokers. This was also pointed out by our small
validation survey. As most recurrences occur within a short
time-span after diagnosis, i.e., within 1 or 2 years, this
distinction might be relevant. Driven by the importance of
the question for clinicians and patients, we however did
perform a secondary analysis to investigate whether
smoking cessation at diagnosis (according to our catego-
rization) could beneﬁcially inﬂuence prognosis. Future
studies should focus on extensive and precise (preferably
prospective) determination of exposure to cigarette smoke
to more accurately assess the prognostic effect of (dura-
tion of) continued smoking after diagnosis.
Lack of association could, in theory, be caused by the
limitations of our study as stated previously. However, our
study ﬁndings may also be explained by the theory of “ﬁeld
cancerization” in the sense that independent and irreversible
(pre-)malignant transformation of cells, spread across the entire
urothelium, has already occurred [22,23]. Next to diagnosis of
multiple synchronous (multifocal) tumors, this explains the
occurrence of metachronous tumors and why termination of
smoking exposure does not beneﬁcially alter recurrence risk.
This study shows that information on smoking status and
history is not useful for improving prediction of disease
outcome or guiding clinical decision making in NMIBC.
Despite the lack of convincing evidence for a prognostic
effect, smoking cessation should still be encouraged byurologists in light of the well-established beneﬁcial inﬂu-
ence on risk of several other diseases, such as cardiovas-
cular disease and second primary cancers.
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